Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/28 10:00:10 pm
58.43 USD   -0.29%
07/28 MERCK : and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker ..
07/27DJBayer Reports Higher Second-Quarter Profit, Raises Guidance
07/26 MERCK : Announces Fourth-Quarter 2016 Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
07/28 MERCK : Patent Issued for Caspofungin Composition (USPTO 9393307)
07/28 MERCK : and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to C..
07/27DJBayer Reports Higher Second-Quarter Profit, Raises Guidance
07/26 MERCK : Announces Fourth-Quarter 2016 Dividend
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
07/25 MERCK : Receives Breakthrough Therapy Designation from FDA and PRIME Status from..
07/22 MERCK : Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (r..
07/21 MERCK ANIMAL HEALTH : Receives FDA Approval of BRAVECTO® (fluralaner topical sol..
07/21 MERCK : Provides Regulatory Update on Biologics Licensing Application for Invest..
07/21 MERCK : Patent Issued for Preparation of Crystalline Forms of Dihydropyrazolopyr..
More news
Sector news : Pharmaceuticals - NEC
07:45aDJSANOFI : Profit Down as Diabetes Drug Sales Slip
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJALEXION PHARMACEUTICALS : Cuts Profit Guidance
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/28 Notable earnings before Friday?s open
07/28 Apple Tops Dogs Of The Dow July Analysis
07/28 Earnings Bonanza Continues, With Internet, Energy Firms In The Spotlight
07/28 Merck Calls Time On U.S. Allergy Market
07/28 Gilead Lives And Dies By Hep C
Advertisement
Financials ($)
Sales 2016 39 492 M
EBIT 2016 13 526 M
Net income 2016 6 428 M
Debt 2016 3 946 M
Yield 2016 3,16%
P/E ratio 2016 25,58
P/E ratio 2017 19,62
EV / Sales 2016 4,20x
EV / Sales 2017 4,19x
Capitalization 161 736 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 61,9 $
Spread / Average Target 5,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.10.62%161 736
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
BRISTOL-MYERS SQUIBB C..8.53%124 630
More Results